Meet Dr. Guilherme Nader-Marta (@guinadermarta.bsky.social), an Advanced Fellow in the Breast Oncology Center at @danafarber.bsky.social. His research interests include #BreastCancer in young patients, #InvasiveLobularCarcinoma, and #radioligand therapy.
@guinadermarta.bsky.social takes part in the ESMO Resilience Task Force Open Forum, highlighting strategies to co-create a resilient oncology workforce and support clinician well-being. #ESMO25
🎥 @guinadermarta.bsky.social of @danafarber.bsky.social discusses PACE trial (NCT03147287) insights on TKa dynamics as prognostic biomarkers and ctDNA-based DNADX tumor subtypes in ER+/HER2- breast cancer:
➡️ https://buff.ly/4gPb4LD ⬅️
@sabcs.bsky.social #SABCS24 #BreastCancer #BCSM
Open access link 🔗 nejmgroup.org/wp-content/uploads/BreastCancerUpdate_0824_lores_FINAL.pdf
Honored to share our article in the @nejm.org Breast Cancer Update discussing two perspectives on anthracycline use in breast cancer—a long-debated topic that remains highly relevant
Grateful to co-author this work with Prof Martine Piccart
@oncoalert.bsky.social
@dfcibreastonc.bsky.social
I'm pleased to announce that the ASCO/Conquer Cancer Foundation Felix Feng Prostate Cancer YIA is now fully endowed and will fund a young prostate cancer investigator every year, in perpetuity. The First Felix Feng YIA recipient will be announced this spring and celebrated at ASCO's annual meeting.
Thank you for your support during #SABCS24 ‼️
OUR COMPLETE SABCS24 Newsletter COMES OUT MONDAY NEXT WEEK
REGISTER AT oncoalert360.com OR buff.ly/48Xpgz0
All OUR TOP pick presented during San Antonio
@elisaagostinetto.bsky.social
@elisabettabonzano.bsky.social
@erikahamilton9.bsky.social
GeparDouze presented at #SABCS24:
Atezolizumab + chemo in stage II/III TNBC did not significantly improve EFS (HR 0.8; 95% CI 0.62-1.03; p=0.08), 4-year EFS: 85.2% vs 81.9%.
pCR increased from 57% to 63%.
@oncoalert.bsky.social
Post-hoc TAILORx analysis: In HR+/HER2-, LN- breast cancer w/ RS ≥31, anthracycline (T-AC) improved 5-year DRFI (96% vs 91%, aHR 0.32, p=0.009) and DRFS vs TC. Benefit strongest in tumors >2cm, increasing with RS
Results are alligned w/ other MammaPrint High 2 results
@oncoalert.bsky.social
Join us tomorrow at Poster Spotlight Session 2!
Join us tomorrow at Poster Spotlight Session 2!
Great presentation on the Association Between Risk-Reducing Surgeries and Survival in Young BRCA Carriers with Breast Cancer by Matteo Lambertini at #SABCS24
Data from >5000 patients show risk-reducing mastectomy and RRSO both improve OS, DFS, and BCFI
@oncoalert.bsky.social
Dr. Harold Burstein discussed the #EMBER3 study data in the #SABCS24 General Session 1.
Amazing discussion by @thomasgrinda.bsky.social
at the Poster Spotlight Session 3 - Highlights on novel therapeutics at #SABCS24 putting into context novel immunotherapy, anti-VEGF and chemotherapy combinations and new HER2-targeted ADC
Happy to present at #SABCS24 the results of 4 studies exploring:
- Prognostic/predictive biomarkers of CDK4/6i beyond progression in the PACE trial
- The influence of pregnancy status on the distribution and prognostic value of Oncotype DX in young women
Join us!
@oncoalert.bsky.social
Biomarker analyses of KN-522 shows most markers (T-cell GEP, HRD, HER2 signaling, PTEN, TNBC subtype) were prognostic but not predictive
High TMB showed a signal for pembro benefit, but only in 8% of pts
Predictive biomarkers for ICI in early TNBC are urgently needed!
@oncoalert.bsky.social
MARGOT trial results presented by Dr Ada Waks at #SABCS2024
No statistically sig pCR benefit (56% vs 46%, p=0.25) between preop margetuximab vs. trastuzumab in combination with paclitaxel-pertuzumab in pts with HER2+ BC and CD16 genotype FF or FV
@oncoalert.bsky.social
@dfcibreastonc.bsky.social
RWE is becoming increasingly vital in cancer research
To improve quality, we need to understand where we stand
Happy to share this major effort analyzing 1251 studies mapping RWE
Standardization & ⬆️ collaboration will be 🔑 to increase the relevance of RWD
@oncoalert.bsky.social
